AIN457 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Chronic Plaque-type Psoriasis
Conditions
Chronic Plaque-type Psoriasis
Trial Timeline
Mar 1, 2010 → Feb 1, 2011
NCT ID
NCT01071252About AIN457 + Placebo
AIN457 + Placebo is a phase 2 stage product being developed by Novartis for Chronic Plaque-type Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01071252. Target conditions include Chronic Plaque-type Psoriasis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01090310 | Phase 3 | Terminated |
| NCT01132612 | Phase 2 | Completed |
| NCT01071252 | Phase 2 | Completed |
| NCT01051817 | Phase 2 | Completed |
| NCT00809614 | Phase 2 | Completed |
| NCT00809159 | Phase 2 | Completed |
| NCT00805480 | Phase 2 | Completed |
| NCT00770965 | Phase 2 | Completed |
| NCT00584740 | Phase 2 | Terminated |
| NCT00669916 | Phase 1/2 | Completed |
| NCT00669942 | Phase 1/2 | Completed |
Competing Products
20 competing products in Chronic Plaque-type Psoriasis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| macitentan 10 mg | BML, Inc. | Phase 3 | 76 |
| KPL-716 + Placebo | Kiniksa Pharmaceuticals | Phase 2 | 47 |
| TERN-701 | Terns Pharmaceuticals | Phase 1/2 | 38 |
| Fludarabine + Cyclophosphamide + PRGN-3007 | Precigen | Phase 1 | 28 |
| LY3556050 + Placebo | Eli Lilly | Phase 2 | 52 |
| THB001 | Third Harmonic Bio | Phase 1 | 25 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 1/2 | 33 |
| Briquilimab | Jasper Therapeutics | Phase 2 | 44 |
| Empagliflozin + Matching placebo | Eli Lilly | Phase 3 | 77 |
| LY3461767 + Placebo | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Venetoclax + Rituximab | Eli Lilly | Phase 3 | 77 |
| LY3526318 + Placebo | Eli Lilly | Phase 2 | 52 |
| Pirtobrutinib | Eli Lilly | Phase 2 | 52 |
| Ibrutinib + LY3214996 | Eli Lilly | Phase 1 | 33 |
| Pirtobrutinib + Acalabrutinib | Eli Lilly | Phase 2 | 52 |
| LYR-210 | Lyra Therapeutics | Phase 2 | 44 |
| LYR-220 Design 1 (Part 1 only) + LYR-220 Design 2 (Part 1 and Part 2) + Bilateral sham procedure control (Part 2) | Lyra Therapeutics | Phase 2 | 44 |
| 480 Mometasone Furoate Sinus Drug Depot | Lyra Therapeutics | Phase 1 | 25 |
| LYR-210 + Sham procedure control | Lyra Therapeutics | Phase 3 | 69 |